早期持续性淋巴细胞减少与脓毒症儿童迁延性多器官衰竭及死亡相关
该多中心观察性队列纳入2015-2017年9个PICU的401例严重脓毒症患儿,比较早期持续性淋巴细胞减少(0-5天内连续2天绝对淋巴细胞计数<1000 cells/µL)与无此表现者。持续性淋巴细胞减少组152例(38%),其复合结局(迁延性MODS或PICU死亡)发生率为43%(66/152)vs 18%(45/249),PICU死亡率为21%(32/152)vs 5%(12/249),均p<0.01;校正基线因素后OR 2.98(95%CI 1.85-4.02;p<0.01)。该组患儿淋巴细胞计数在研究期间多未恢复,全血经脂多糖刺激后肿瘤坏死因子-α反应最低值更低,而0-3天炎症标志物(C反应蛋白和铁蛋白)最高值更高(p<0.01)。作者认为该证据支持对以早期持续性淋巴细胞减少进行风险分层的儿童严重脓毒症患者测试免疫支持治疗。
要点
- 严重脓毒症患儿中38%(152/401)存在早期持续性淋巴细胞减少(0-5天内连续2天绝对淋巴细胞计数<1000 cells/µL)。
- 持续性淋巴细胞减少组复合结局(迁延性MODS或PICU死亡)发生率为43%(66/152)vs 18%(45/249),p<0.01。
- 持续性淋巴细胞减少组PICU死亡率为21%(32/152)vs 5%(12/249),p<0.01;迁延性MODS发生率为39%(59/152)vs 17%(43/249)。
- 校正基线因素后,持续性淋巴细胞减少与复合结局的OR为2.98(95%CI 1.85-4.02;p<0.01)。
- 持续性淋巴细胞减少组淋巴细胞计数在研究期间多未恢复,全血经脂多糖刺激后肿瘤坏死因子-α反应最低值更低,0-3天C反应蛋白和铁蛋白最高值更高(p<0.01)。
适用人群与场景
- 2015-2017年国家儿童重症监护研究网络(National Institutes of Health Collaborative Pediatric Critical Care Research Network)9个PICU收治的严重脓毒症患儿,且留置动脉和/或中心静脉导管。
诊断标准与关键阈值
- 早期持续性淋巴细胞减少定义为研究第0-5天内连续2天绝对淋巴细胞计数<1000 cells/µL。
研究设计与关键结果
- 研究类型:观察性队列研究,9个PICU,2015-2017年,纳入401例严重脓毒症患儿。
- 持续性淋巴细胞减少组152例(38%),无持续性淋巴细胞减少组249例;前者年龄更大、病情严重度更高,更可能有实体器官移植或恶性肿瘤等基础合并症。
- 主要复合终点(迁延性MODS或PICU死亡):持续性淋巴细胞减少组66/152(43%)vs 无持续性淋巴细胞减少组45/249(18%),p<0.01。
- 迁延性MODS:持续性淋巴细胞减少组59/152(39%)vs 无持续性淋巴细胞减少组43/249(17%)。
- PICU死亡:持续性淋巴细胞减少组32/152(21%)vs 无持续性淋巴细胞减少组12/249(5%),p<0.01。
- 校正入组时基线因素后,持续性淋巴细胞减少与复合结局的OR为2.98(95%CI 1.85-4.02;p<0.01)。
- 淋巴细胞计数轨迹显示,持续性淋巴细胞减少组患儿在研究期间淋巴细胞计数多未恢复,全血经脂多糖刺激后肿瘤坏死因子-α反应最低值更低,0-3天炎症标志物(C反应蛋白和铁蛋白)最高值更高(p<0.01)。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该证据支持对以早期持续性淋巴细胞减少进行风险分层的儿童严重脓毒症患者测试免疫支持治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Sepsis-associated immune suppression correlates with poor outcomes. Adult trials are evaluating immune support therapies. Limited data exist to support consideration of immunomodulation in pediatric sepsis. We tested the hypothesis that early, persistent lymphopenia predicts worse outcomes in pediatric severe sepsis.
DESIGN: Observational cohort comparing children with severe sepsis and early, persistent lymphopenia (absolute lymphocyte count < 1,000 cells/µL on 2 d between study days 0-5) to children without. The composite outcome was prolonged multiple organ dysfunction syndrome (MODS, organ dysfunction beyond day 7) or PICU mortality.
SETTING: Nine PICUs in the National Institutes of Health Collaborative Pediatric Critical Care Research Network between 2015 and 2017.
PATIENTS: Children with severe sepsis and indwelling arterial and/or central venous catheters.
INTERVENTIONS: Blood sampling and clinical data analysis.
MEASUREMENTS AND MAIN RESULTS: Among 401 pediatric patients with severe sepsis, 152 (38%) had persistent lymphopenia. These patients were older, had higher illness severity, and were more likely to have underlying comorbidities including solid organ transplant or malignancy. Persistent lymphopenia was associated with the composite outcome prolonged MODS or PICU mortality (66/152, 43% vs 45/249, 18%; p < 0.01) and its components prolonged MODS (59/152 [39%] vs 43/249 [17%]), and PICU mortality (32/152, 21% vs 12/249, 5%; p < 0.01) versus children without. After adjusting for baseline factors at enrollment, the presence of persistent lymphopenia was associated with an odds ratio of 2.98 (95% CI [1.85-4.02]; p < 0.01) for the composite outcome. Lymphocyte count trajectories showed that patients with persistent lymphopenia generally did not recover lymphocyte counts during the study, had lower nadir whole blood tumor necrosis factor-α response to lipopolysaccharide stimulation, and higher maximal inflammatory markers (C-reactive protein and ferritin) during days 0-3 ( p < 0.01).
CONCLUSIONS: Children with severe sepsis and persistent lymphopenia are at risk of prolonged MODS or PICU mortality. This evidence supports testing therapies for pediatric severe sepsis patients risk-stratified by early, persistent lymphopenia.
参考来源
- Podd BS, Banks RK, Reeder R, et al. Early, Persistent Lymphopenia Is Associated With Prolonged Multiple Organ Failure and Mortality in Septic Children. Crit Care Med. 2023. PMID: 37462434. doi:10.1097/CCM.0000000000005993
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。